Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utility of Oral Dexmedetomidine as the Sole Sedative Agent in Pediatric Population Undergoing MRI
NCT05619627Phase 1Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of dexmedetomidine in Anesthesia (6 arms). Primary endpoint: Oral dexmedetomidine dose with adverse event below moderate risk to obtain adequate MRI study at 70 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
Anesthesia
Beyond the preview
Go deeper on NCT05619627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05619627.